Michael Gelinsky,
Professor and Head, Center for Translational Bone, Joint and Soft Tissue Research, Faculty of Medicine,
Technische Universität Dresden
Michael Gelinsky received his PhD in Chemistry from Freiburg University (Germany). In 1999 he moved to TU Dresden and worked for around 10 years at the department of Materials Science, heading his own group at the newly founded Max Bergmann Center of Biomaterials from 2002. In 2010 he was appointed Full Professor at the Faculty of Medicine and head of the Centre for Translational Bone, Joint and Soft Tissue Research (tu-dresden.de/med/tfo). His work is focused on biomaterials and scaffold development, tissue engineering and regenerative therapies, mostly for musculoskeletal tissues. His group is also very active in the field of additive manufacturing of implants and biofabrication technologies. Michael Gelinsky is currently President of the German Society for Biomaterials, is a member of the Board of Directors of the International Society for Biofabrication (ISBF) and has been appointed as coordinator of an ESA Topical Team on “3D Bioprinting of living tissue for utilization in space exploration and extraterrestrial human settlements”. He also is member of the ESA Facility Science Team (FST) for the development of a bioprinter and 3D cell culture system for the ISS.
Bioprinting of Mammalian and Non-mammalian Cells for Applications in Medicine, Biotechnology and Space Exploration
Monday, 7 November 2022 at 16:00
Add to Calendar ▼2022-11-07 16:00:002022-11-07 17:00:00Europe/LondonBioprinting of Mammalian and Non-mammalian Cells for Applications in Medicine, Biotechnology and Space ExplorationBioprinting and Bioink Innovations for 3D-Tissues 2022 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
Bioprinting has developed tremendously over the last 10-15 years. While the technology at the beginning has been investigated only for biomedical applications, utilizing human or other mammalian cells, in the meanwhile also non-mammalian cells like green algae, cyanobacteria or plant-derived cells have been bioprinted successfully. This opens new opportunities for applications in biotechnology. Both is also of interest for space flight: for long-term space exploratory missions and extra-terrestrial human settlements, e. g. on Moon or Mars, the astronauts must be able to treat health problems on site as a fast return to Earth is impossible. 3D bioprinting is a promising technology which might allow fabrication of tissue constructs like skin and bone with limited equipment and materials which mostly could be produced locally. Bioprinted constructs containing algae might be utilized for oxygen production and wastewater treatment. The presentation will give an overview about the work of the lab which has pioneered bioprinting of non-mammalian cells (“green bioprinting”) and which is closely connected to the European Space Agency ESA concerning the investigation of bioprinting for applications in space.
Add to Calendar ▼2022-11-07 00:00:002022-11-08 00:00:00Europe/LondonBioprinting and Bioink Innovations for 3D-Tissues 2022Bioprinting and Bioink Innovations for 3D-Tissues 2022 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2022-11-07 16:00:002022-11-07 17:00:00Europe/LondonBioprinting of Mammalian and Non-mammalian Cells for Applications in Medicine, Biotechnology and Space ExplorationBioprinting and Bioink Innovations for 3D-Tissues 2022 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
